The oral S1P1 and S1P5 receptor agonist drug – now given the trade name Zeposia – was billed as one of the top 2020 drug launches to watch by Clarivate last month, before the COVID-19 outbreak ...

Originally developed by Celgene ahead of its $74 billion takeover by BMS, Zeposia has been trumpeted as one of the top 2020 drug launches to watch by Clarivate, which expects sales to reach $1.6 ...